Precision Medicine in Cholangiocarcinoma: Past, Present, and Future

Precision Medicine in Cholangiocarcinoma: Past, Present, and Future

Cholangiocarcinoma (CCA), or biliary tract cancer, has a poor prognosis. The median survival time among patients with CCA is under 2 years from diagnosis, and the global 5-year survival rate is only 10%. First-line therapy with chemotherapeutic agents, gemcitabine plus cisplatin, has traditionally b...

Full description

Bibliographic Details
Main Authors:	Chi-Yuan Cheng, Chiao-Ping Chen, Chiao-En Wu
Format:	Article
Language:	English
Published:	MDPI AG 2022-06-01
Series:	Life
Subjects:	cholangiocarcinoma (CCA) targeted therapy NTRK IDH1 FGFR2 BRAF
Online Access:	https://www.mdpi.com/2075-1729/12/6/829

Similar Items

Molecular Subtypes and Precision Oncology in Intrahepatic Cholangiocarcinoma
by: Carolin Czauderna, et al.
Published: (2021-06-01)

Clinical management of intrahepatic cholangiocarcinoma: surgical approaches and systemic therapies
by: Samantha M. Ruff, et al.
Published: (2024-01-01)

FGFR Inhibitors in Cholangiocarcinoma—A Novel Yet Primary Approach: Where Do We Stand Now and Where to Head Next in Targeting This Axis?
by: Paulina Chmiel, et al.
Published: (2022-12-01)

Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue
by: Giovanni Brandi, et al.
Published: (2023-04-01)

Molecular Profiling in Daily Clinical Practice: Practicalities in Advanced Cholangiocarcinoma and Other Biliary Tract Cancers
by: Angela Lamarca, et al.
Published: (2020-09-01)

Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors
by: Alessandro Rizzo
Published: (2021-05-01)

Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma
by: Su Min Cho, et al.
Published: (2022-05-01)

Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future
by: Alessandro Rizzo, et al.
Published: (2022-01-01)

Nanoparticle-mediated therapeutic management in cholangiocarcinoma drug targeting: Current progress and future prospects
by: Chunkang Liu, et al.
Published: (2023-02-01)

The expression, clinical relevance, and prognostic significance of HJURP in cholangiocarcinoma
by: Yang Yang, et al.
Published: (2022-07-01)

Targeted Therapies for Perihilar Cholangiocarcinoma
by: Simon Gray, et al.
Published: (2022-03-01)

Isocitrate dehydrogenase 1 mutation in cholangiocarcinoma impairs tumor progression by sensitizing cells to ferroptosis
by: Su Li, et al.
Published: (2022-05-01)

Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options
by: Nicola Personeni, et al.
Published: (2020-11-01)

Cholangiocarcinoma Insights: Established Foundations and Cutting-Edge Innovations from Dr. James Cleary’s Pioneering Research
by: Viviana Cortiana, et al.
Published: (2024-02-01)

The Importance of Molecular Testing in the Treatment of Cholangiocarcinoma
by: David Malka, et al.
Published: (2020-11-01)

Favorable Outcomes in FGFR Fusion-Positive Cholangiocarcinomas and Evolution on Treatment Noted on Circulating Tumor DNA Liquid Biopsies
by: Pashtoon Murtaza Kasi
Published: (2020-08-01)

IDH Signalling Pathway in Cholangiocarcinoma: From Biological Rationale to Therapeutic Targeting
by: Massimiliano Salati, et al.
Published: (2020-11-01)

Terminal fucosylation of haptoglobin in cancer-derived exosomes during cholangiocarcinoma progression
by: Hyewon Choi, et al.
Published: (2023-04-01)

Application of AI on cholangiocarcinoma
by: Jianhao Huang, et al.
Published: (2024-01-01)

Oncogenic activation revealed by FGFR2 genetic alterations in intrahepatic cholangiocarcinomas
by: Xiaohong Pu, et al.
Published: (2023-11-01)

The Evolving Role of FGFR2 Inhibitors in Intrahepatic Cholangiocarcinoma: From Molecular Biology to Clinical Targeting
by: Salati M, et al.
Published: (2021-10-01)

Pemigatinib in Intrahepatic Cholangiocarcinoma: A Work in Progress
by: Gennaro Gadaleta-Caldarola, et al.
Published: (2022-10-01)

Ferroptosis gene signature in cholangiocarcinoma
by: Pradeep Reddy Cingaram
Published: (2022-12-01)

NTRK Fusions, from the Diagnostic Algorithm to Innovative Treatment in the Era of Precision Medicine
by: Federica Zito Marino, et al.
Published: (2020-05-01)

Clinical Utility of Ivosidenib in the Treatment of IDH1-Mutant Cholangiocarcinoma: Evidence To Date
by: Uson Junior PLS, et al.
Published: (2023-09-01)

Dysbiosis in the Human Microbiome of Cholangiocarcinoma
by: Benchen Rao, et al.
Published: (2021-11-01)

Leakage and Stenosis of the Hepaticojejunostomy Following Surgery for Perihilar Cholangiocarcinoma
by: Jan Bednarsch, et al.
Published: (2020-05-01)

Clinical experience with pemigatinib for previously treated metastatic cholangiocarcinoma: practical considerations from clinical cases
by: Jonathan Wadsley, et al.
Published: (2023-08-01)

Identification and In-Depth Analysis of the Novel FGFR2-NDC80 Fusion in a Cholangiocarcinoma Patient: Implication for Therapy
by: Alexander Scheiter, et al.
Published: (2021-03-01)

Current Surgical Management of Peri-Hilar and Intra-Hepatic Cholangiocarcinoma
by: Andrea Lauterio, et al.
Published: (2021-07-01)

Cholangiocarcinogenesis and targeted therapy for cholangiocarcinoma
by: A. A. Gritskevich, et al.
Published: (2021-12-01)

A Cancer-Favoring, Engineered Vaccinia Virus for Cholangiocarcinoma
by: So Young Yoo, et al.
Published: (2019-10-01)

Targeting FGFRs Using PD173074 as a Novel Therapeutic Strategy in Cholangiocarcinoma
by: Brinda Balasubramanian, et al.
Published: (2023-04-01)

Molecular Landscape and Therapeutic Strategies in Cholangiocarcinoma: An Integrated Translational Approach towards Precision Medicine
by: Marco Casadio, et al.
Published: (2021-05-01)

Targeting the Fibroblast Growth Factor Receptor (FGFR) in Advanced Cholangiocarcinoma: Clinical Trial Progress and Future Considerations
by: Patrick C. Lee, et al.
Published: (2021-04-01)

Prognostic Significance of the Systemic Immune-Inflammation Index in Patients With Cholangiocarcinoma: A Meta-Analysis
by: Xue-chun Liu, et al.
Published: (2022-07-01)

Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma
by: C. Peraldo-Neia, et al.
Published: (2018-06-01)

Flower-like Composite Material Delivery of Co-Packaged Lenvatinib and Bufalin Prevents the Migration and Invasion of Cholangiocarcinoma
by: Zhouyu Ning, et al.
Published: (2022-06-01)

<i>IDH1</i> Targeting as a New Potential Option for Intrahepatic Cholangiocarcinoma Treatment—Current State and Future Perspectives
by: Fabiana Crispo, et al.
Published: (2020-08-01)

FDFT1/FGFR2 rearrangement: A newly identified anlotinib-sensitive FGFR2 variant in cholangiocarcinoma
by: Chunye Huang, et al.
Published: (2022-01-01)